Developing RNAi Therapeutics (Part II)
An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.
22 views
00:09:24 - Uploaded by Song Essinova, LLC on September 14, 2009
Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.
In this segment, Dr. Lu responds to questions about potential risks inherent in RNAi therapeutics in terms of toxicity and specificity, and explains ways to mitigate those risks. He also provides his take on where "breakthrough" may emerge and discusses Sirnaomics clinical strategy in developing siRNA drugs.
Tags: RNAi, siRNA, miRNA, oligonucleotides, Sirnaomics, Patrick Lu, IBC, DDD
COMMENTS
There are 0 comments. You must be logged in to comment.
Therapeutics & Vaccines
-
Vitae's Computationally-grown Molecules and Four Tough Diseases
-
Expanding Access to Patients in Need Around the World
-
Five Prime Therapeutics - Protein Medicines
-
Chemokine Therapeutics from ChemoCentryx
-
Developing RNAi Therapeutics (Part I)
-
Developing RNAi Therapeutics (Part II)
-
Developing RNAi Therapeutics (Part III)
